4//SEC Filing
Solexa, Inc. 4
Accession 0001140484-05-000017
CIK 0000913275operating
Filed
Jul 13, 8:00 PM ET
Accepted
Jul 14, 7:36 PM ET
Size
29.0 KB
Accession
0001140484-05-000017
Insider Transaction Report
Form 4
Solexa, Inc.SLXA
FLEMING JONATHAN
10% Owner
Transactions
- Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying) - Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.) - Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total
LYTTON MICHAEL
10% Owner
Transactions
- Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying) - Award
Common
2005-07-12+1,986→ 3,015,508 total - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.)
WALTON ALAN G
10% Owner
Transactions
- Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying)
CARTHY MARK
10% Owner
Transactions
- Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying) - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying)
OXFORD BIOSCIENCE PARTNERS IV LP
10% Owner
Transactions
- Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying)
MRNA FUND II LP
10% Owner
Transactions
- Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.) - Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying)
OBP MANAGEMENT IV LP
10% Owner
Transactions
- Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying) - Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.) - Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.)
BARNES JEFFREY T
10% Owner
Transactions
- Award
Common
2005-07-12+1,986→ 3,015,508 total - Purchase
Warrant (right to buy)
2005-07-12+272,268→ 272,268 totalExercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (272,268 underlying) - Purchase
Common
2005-07-12$4.00/sh+544,536$2,178,144→ 3,013,522 total - Purchase
Common
2005-07-12$4.00/sh+5,464$21,856→ 30,235 total(indirect: By mRNA Fund II L.P.) - Purchase
Warrant (right to buy)
2005-07-12+2,732→ 2,732 total(indirect: By mRNA Fund II L.P.)Exercise: $5.00From: 2006-01-08Exp: 2010-07-12→ Common (2,732 underlying) - Award
Common
2005-07-12+20→ 30,255 total(indirect: By mRNA Fund II L.P.)
Footnotes (4)
- [F1]Securities held of record by Oxford Bioscience Partners IV L.P. ("Oxford IV"). By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA Fund II L.P. ("mRNA") may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. OBP Management IV L.P. ("OBP IV") (as the general partner of Oxford IV and mRNA II), may also be deemed to own beneficially the shares held of record by Oxford IV and mRNA II. Each of Messrs. Barnes, Carthy, Fleming, Lytton, and Walton, the individual general partners of OBP IV, may be deemed to own beneficially the shares held by Oxford IV and mRNA II. The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
- [F2]The shares were issued in connection with the reallocation of an aggregate of 7,198 shares of common stock of Solexa, Inc. (the "Company") to the former shareholders of Solexa Limited in connection with the business combination between the Company and Solexa Limited completed on March 4, 2005.
- [F3]Securities held of record by mRNA. By virtue of their relationship as affiliated limited partnerships, whose sole general partner shares individual general partners, Oxford IV and mRNA may be deemed to share voting power and the power to direct the disposition of the shares which each partnership owns of record. OBP IV (as the general partner of Oxford IV and mRNA II), may also be deemed to own beneficially the shares held of record by Oxford IV and mRNA II. Each of Messrs. Barnes, Carthy, Fleming, Lytton, and Walton, the individual general partners of OBP IV, may be deemed to own beneficially the shares held by Oxford IV and mRNA II. The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.
- [F4]If, at any time prior to January 12, 2008, Solexa, Inc. issues additional shares of Common Stock or rights, warrants, options or other securities or debt convertible, exercisable or exchangeable for shares of Common Stock or otherwise entitling any individual or entity to acquire shares of Common Stock at an effective net price to the Company per share of Common Stock less than four dollars ($4.00) the Exercise Price shall be reduced in accordance with the terms of the Warrant to Purchase Common Stock dated as of May 6, 2005.
Issuer
Solexa, Inc.
CIK 0000913275
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000913275
Filing Metadata
- Form type
- 4
- Filed
- Jul 13, 8:00 PM ET
- Accepted
- Jul 14, 7:36 PM ET
- Size
- 29.0 KB